Table 1 Patient demographics and baseline characteristics (FAS)
|  | PHN (n = 89) | HIV-AN (n = 5) | NBP (n = 50) | CRNP (n = 22) | PONP (n = 198) | Other (n = 56) | Overall (n = 420) |
|---|---|---|---|---|---|---|---|
Gender, n (%) | |||||||
 Male | 36 (40.4) | 5 (100) | 17 (34.0) | 5 (22.7) | 75 (37.9) | 29 (51.8) | 167 (39.8) |
 Female | 53 (59.6) | 0 | 33 (66.0) | 17 (77.3) | 123 (62.1) | 27 (48.2) | 253 (60.2) |
Ethnicity, n (%) | |||||||
 Caucasian | 88 (98.9) | 4 (80.0) | 49 (98.0) | 19 (86.3) | 185 (93.4) | 55 (98.2) | 400 (95.2) |
 Asian | 0 | 1 (20.0) | 0 | 0 | 2 (1.0) | 0 | 3 (0.7) |
 Black/African/Caribbean | 1 (1.1) | 0 | 1 (2.0) | 1 (4.5) | 8 (4.0) | 1 (1.8) | 12 (2.9) |
 Mixed/multiple ethnic groups | 0 | 0 | 0 | 1 (4.5) | 1 (0.5) | 0 | 2 (0.5) |
 Not recorded | 0 | 0 | 0 | 1 (4.5) | 2 (1.0) | 0 | 3 (0.7) |
Median age, years (min–max) | 72 (37–98) | 52 (33–59) | 63 (27–90) | 59 (42–76) | 54 (21–83) | 60 (24–86) | 61 (21–98) |
Median duration of pain, years (min–max) | 1.0 (0.1–73.2) | 0.3 (0.2–13.6) | 2.6 (0–40.0) | 2.2 (0.2–8.1) | 2.6 (0.1–50.1) | 2.2 (0.1–29.2) | 2.1 (0–73.2) |
Treatment pathway, n (%) | |||||||
 Primary | 13 (14.6) | 1 (20.0) | 20 (40.0) | 2 (9.1) | 35 (17.7) | 10 (17.9) | 81 (19.3) |
 Secondary | 48 (53.9) | 3 (60.0) | 14 (28.0) | 13 (59.1) | 78 (39.4) | 24 (42.9) | 180 (42.9) |
 Tertiary | 28 (31.5) | 1 (20.0) | 16 (32.0) | 7 (31.8) | 85 (42.9) | 22 (39.3) | 159 (37.9) |
Baseline ‘average pain’,a n (SD) | 7.1 (2.0) | 6.4 (1.5) | 7.3 (2.0) | 7.2 (1.5) | 6.8 (1.8) | 6.9 (1.8) | 6.9 (1.8) |
Mean number of concomitant medications,b n (SD) | 1.8 (1.5) | 1.4 (1.5) | 1.5 (1.6) | 2.2 (1.4) | 1.9 (1.5) | 1.7 (1.4) | 1.8 (1.5) |